Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia
Abebech Tewabe Gelaye,1 Mohammed Assen Seid,1 Lemlem Daniel Baffa2 1Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Human Nutrition, Institute of Public Health, College of Medicine and Health Science...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/angiotensin-converting-enzyme-inhibitor-dose-optimization-and-its-asso-peer-reviewed-fulltext-article-VHRM |
| _version_ | 1828516778573037568 |
|---|---|
| author | Gelaye AT Seid MA Baffa LD |
| author_facet | Gelaye AT Seid MA Baffa LD |
| author_sort | Gelaye AT |
| collection | DOAJ |
| description | Abebech Tewabe Gelaye,1 Mohammed Assen Seid,1 Lemlem Daniel Baffa2 1Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Human Nutrition, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Abebech Tewabe Gelaye, Email abie.tewabe@gmail.comIntroduction: Angiotensin-converting enzyme inhibitors dose optimizations (ACEIs) are essential to boost the treatment outcome in heart failure patients (HF) with reduced ejection fraction. Therefore, the main purpose of this study was to evaluate dose optimization and associated factors of ACEIs among HF patients.Method: An institutional-based retrospective study was conducted on 256 study participants from May 20 to August 30, 2020 in ambulatory care clinic at Felege Hiwot Comprehensive Specialized Hospital. A systematic random sampling method was carried out to select study participants. Data were collected from the patient interview and the review of medical records. Epidata and SPSS version 22 were used for data entry and analysis. A bivariate logistic regression analysis was done to determine the association of independent variables with a dose optimization of ACEIs.Results: The mean age of the subjects in the study was 53.82 years with a standard deviation (SD) of 17.067 and more than half of (60.9%) the patients were unable to read and write. Among participants who were receiving ACEIs, only 30.6% were taking an optimal dose. Age ≥ 65 years (AOR 5.04 (2.81– 12.56)) and a dose of furosemide ≥ 40 mg (AOR, 2.62 (1.28– 16.74)) were significantly associated with the suboptimal dose of ACEIs.Conclusion: Only one-third of patients received the optimum dose of ACEIs. Older age and dose of furosemide greater > 40 mg were significantly associated with suboptimal dosing of ACEIs. Therefore, more attention must be given to older patients with HF in order to optimize the dose of ACEIs administered.Keywords: ACEIS, dose optimization, HF, Ethiopia |
| first_indexed | 2024-12-11T18:32:44Z |
| format | Article |
| id | doaj.art-9951388caa7344659755d22166b950dd |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-11T18:32:44Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-9951388caa7344659755d22166b950dd2022-12-22T00:54:52ZengDove Medical PressVascular Health and Risk Management1178-20482022-07-01Volume 1848149376413Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, EthiopiaGelaye ATSeid MABaffa LDAbebech Tewabe Gelaye,1 Mohammed Assen Seid,1 Lemlem Daniel Baffa2 1Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Human Nutrition, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Abebech Tewabe Gelaye, Email abie.tewabe@gmail.comIntroduction: Angiotensin-converting enzyme inhibitors dose optimizations (ACEIs) are essential to boost the treatment outcome in heart failure patients (HF) with reduced ejection fraction. Therefore, the main purpose of this study was to evaluate dose optimization and associated factors of ACEIs among HF patients.Method: An institutional-based retrospective study was conducted on 256 study participants from May 20 to August 30, 2020 in ambulatory care clinic at Felege Hiwot Comprehensive Specialized Hospital. A systematic random sampling method was carried out to select study participants. Data were collected from the patient interview and the review of medical records. Epidata and SPSS version 22 were used for data entry and analysis. A bivariate logistic regression analysis was done to determine the association of independent variables with a dose optimization of ACEIs.Results: The mean age of the subjects in the study was 53.82 years with a standard deviation (SD) of 17.067 and more than half of (60.9%) the patients were unable to read and write. Among participants who were receiving ACEIs, only 30.6% were taking an optimal dose. Age ≥ 65 years (AOR 5.04 (2.81– 12.56)) and a dose of furosemide ≥ 40 mg (AOR, 2.62 (1.28– 16.74)) were significantly associated with the suboptimal dose of ACEIs.Conclusion: Only one-third of patients received the optimum dose of ACEIs. Older age and dose of furosemide greater > 40 mg were significantly associated with suboptimal dosing of ACEIs. Therefore, more attention must be given to older patients with HF in order to optimize the dose of ACEIs administered.Keywords: ACEIS, dose optimization, HF, Ethiopiahttps://www.dovepress.com/angiotensin-converting-enzyme-inhibitor-dose-optimization-and-its-asso-peer-reviewed-fulltext-article-VHRMangiotensin-converting enzyme inhibitorsdose optimizationheart failureethiopia |
| spellingShingle | Gelaye AT Seid MA Baffa LD Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia Vascular Health and Risk Management angiotensin-converting enzyme inhibitors dose optimization heart failure ethiopia |
| title | Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia |
| title_full | Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia |
| title_fullStr | Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia |
| title_full_unstemmed | Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia |
| title_short | Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia |
| title_sort | angiotensin converting enzyme inhibitor dose optimization and its associated factors at felege hiwot comprehensive specialized hospital bahir dar ethiopia |
| topic | angiotensin-converting enzyme inhibitors dose optimization heart failure ethiopia |
| url | https://www.dovepress.com/angiotensin-converting-enzyme-inhibitor-dose-optimization-and-its-asso-peer-reviewed-fulltext-article-VHRM |
| work_keys_str_mv | AT gelayeat angiotensinconvertingenzymeinhibitordoseoptimizationanditsassociatedfactorsatfelegehiwotcomprehensivespecializedhospitalbahirdarethiopia AT seidma angiotensinconvertingenzymeinhibitordoseoptimizationanditsassociatedfactorsatfelegehiwotcomprehensivespecializedhospitalbahirdarethiopia AT baffald angiotensinconvertingenzymeinhibitordoseoptimizationanditsassociatedfactorsatfelegehiwotcomprehensivespecializedhospitalbahirdarethiopia |